NextCell Pharma AB
The answer first
Does NextCell Pharma beat the market?
No, NextCell Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 61% of Nordic stocks
- Quality73
- Value78
- Trend20
No. 46 of 195 in healthcare
Max for seven days
Follow NextCell Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about NextCell Pharma
Your first answer is free, no account needed.
Do you own NextCell Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with NextCell Pharma and a few more. Free, no card.
Super Stock+44.6%In short
- NextCell Pharma has fallen 71.0% over the past year, including dividends.
- Overall, NextCell Pharma ranks better than 61% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 94.0%. The price is 98.9% below its peak now.
What do analysts think of NextCell Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 61% of Nordic stocks.
No. 46 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 77 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.16
- Return on equityProfit divided by equity−94.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 14 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.6
- P/SPrice divided by sales2.7
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 125 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−80.7%
- 6 months−82.0%
- 9 months−85.5%
- 12 months−71.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own NextCell Pharma
One fund we follow owns NextCell Pharma. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About NextCell Pharma
NextCell Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.


See the full analysis of NextCell Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card